|Bid||0.000 x 1100|
|Ask||0.000 x 1800|
|Day's Range||0.6120 - 0.6638|
|52 Week Range||0.5700 - 1.3000|
|Beta (3Y Monthly)||-0.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
Oncobiologics, Inc. (ONS) (the “Company”) today announced several key corporate events that enhance the Company’s ability to advance the development of its lead product candidate, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). The Company has changed its name from Oncobiologics, Inc. to Outlook Therapeutics, Inc., effective immediately. The Company will continue to be listed on the Nasdaq Capital Market and its common stock and Series A warrants will begin trading under the ticker symbols “OTLK” and “OTLKW,” respectively, beginning on Tuesday, December 4, 2018.
Oncobiologics, Inc. (ONS) today announced that it has begun dosing patients in its first clinical trial for ONS-5010, a proprietary ophthalmic bevacizumab product candidate, in patients with wet age related macular degeneration (wet AMD). This first clinical study for ONS-5010, the Company’s lead product candidate, is being conducted outside of the United States and is designed to serve as the first of two adequate and well controlled studies for wet AMD. The U.S. portion of the second study is scheduled to begin in early 2019 upon the submission of an investigational new drug (IND) application. The Company’s wet AMD clinical program was reviewed at a successful end of Phase 2 meeting held with the U.S. Food and Drug Administration (FDA) conducted earlier in 2018. If the program is successful, it will support the Company’s plans to submit for regulatory approval in multiple markets in 2020. The Company is developing ONS-5010 as an innovative therapy and not using the biosimilar drug development pathway.
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on Evogene Ltd (NASDAQ: EVGN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EVGN as the Company's latest news hit the wire. On May 29, 2018, the Company, which is a leading biotechnology organization developing novel products for life science markets, and BASF, which is one of the world's leading chemical Companies, declared on May 29, 2018, that they have signed a new collaboration agreement for the development of novel insecticides based on new binding areas (Site-of-Action or ‘SoA') on key insecticidal target proteins. Active-Investors.com is currently working on the research report for Oncobiologics, Inc. (NASDAQ: ONS), which also belongs to the Healthcare sector as the Company Evogene.
In this analysis, my focus will be on developing a perspective on Oncobiologics Inc’s (NASDAQ:ONS) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...
Leading Oncobiologics Inc (NASDAQ:ONS) as the CEO, Pankaj Mohan took the company to a valuation of US$23.68M. Understanding how CEOs are incentivised to run and grow their company is anRead More...
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Oncobiologics Inc’s (NASDAQ:ONS) track record on a high level, to giveRead More...
In this article, I will take a quick look at Oncobiologics Inc’s (NASDAQ:ONS) recent ownership structure – an unconventional investing subject, but an important one. When it comes to ownershipRead More...